All In Biotech

Drug Trial Radar · NCT05620017

Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection

A Multicenter, Open Phase I Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Initial Efficacy of BAT8008 for Injection in Patients With Advanced Solid Tumor

Last checked: Nov 19, 2026Latest source record: Feb 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

182

Planned (sponsor's estimate)

Start

Nov 30, 2022

Primary completion

May 31, 2027

Study completion May 31, 2027

Sponsor

Lead sponsor
Bio-Thera SolutionsIndustry
Sponsor type
Industry
First posted
Nov 17, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Objectives:To evaluate the safety and tolerability of BAT8008 for injection in patients with advanced solid tumors, explore the maximum tolerated dose (MTD), and provide the recommended dose for subsequent clinical trials.

Conditions

  • Advanced Solid Tumors

Interventions

  • BAT8008 for InjectionDrug

    Intravenous infusion, once every 2 weeks (Q2W). It is recommended that the infusion time of the first cycle should be ≥ 3 hours. If no infusion reaction occurs, the subsequent circulation can be completed within 1-2 hours.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicity (DLT)Time frame: At the end of Cycle 1( first cycle is 21 days, subsequent cycles are 14 days)
  2. Maximum tolerated dose (MTD)Time frame: At the end of Cycle 1( first cycle is 21 days, subsequent cycles are 14 days)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Affiliated Cancer Hospital of Chongqing University

    Chongqing, Chongqing Municipality, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.